Genvoya
Gilead and PAHO announce milestone partnership to accelerate access to HIV pre-exposure treatment
The agreement will improve access to twice-yearly Lenacapavir across Latin America and the Caribbean
Gilead opens new research centre bringing together oncology, inflammation and research data science teams
The centre in California supports the company’s $32bn US investment
AbbVie’s Rinvoq approved by European Commission for non-segmental vitiligo
Rinvoq is the first and only systemic medication approved in the EU for NSV
Gilead’s New Drug Application for Yeztugo accepted by US FDA
The investigational once-weekly oral treatment could be the first long-acting pill for HIV prevention
CSL’s Privigen approved as measles treatment by European Commission
Cases of measles have been rising in Europe since 2023
Lilly’s early Alzheimer’s disease treatment approved in the EU
Marketing authorisation follows positive late-stage trial results
Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use
An estimated 1.2 million people in the US are currently living with the virus
Sanofi’s Sarclisa approved by EC to treat newly diagnosed multiple myeloma
The drug is already approved in the EU across three other multiple myeloma indications
J&J announces EC approval of Imbruvica in previously untreated mantle cell lymphoma
The drug is already approved in the EU to treat relapsed or refractory cases of the blood cancer
Johnson & Johnson’s Darzalex approved by EC as first treatment for high-risk SMM
The early precursor of active multiple myeloma accounts for around 15% of all new multiple myeloma cases
Roche’s Itovebi granted EC approval to treat advanced breast cancer patients
Hormone receptor-positive breast cancer accounts for around 70% of all breast cancer cases
EC approves SpringWorks Therapeutics’ Ezmekly to treat rare genetic disorder NF1
Neurofibromatosis type 1 affects an estimated 135,000 people in the EU